Categories: Prescription Medication
Description:
Cabazitaxel is a chemotherapy agent used in metastatic castration-resistant prostate cancer (mCRPC), particularly in men whose disease has progressed after treatment with docetaxel. It belongs to the taxane class, like docetaxel, but is less affected by resistance mechanisms, making it effective even in previously treated patients.
It is administered by IV infusion, typically every 3 weeks, often alongside prednisone. The TROPIC trial demonstrated that cabazitaxel improves overall survival and progression-free survival in mCRPC post-docetaxel. Side effects include neutropenia, fatigue, diarrhea, and peripheral neuropathy, and it requires careful monitoring, especially in older or frail patients. It is considered a standard second-line chemotherapy option after docetaxel failure.
Treatment For:
AI generated Summary: Based on the provided information, there are no reviews available for the effectiveness of Cabazitaxel as a treatment for Metastatic Castration-Resistant Prostate Cancer. Without any user reviews or ratings, it is not possible to determine the efficacy of this treatment for the specified condition.
The information, including but not limited to, text, graphics, images and other material contained on this website/app are for informational purposes only. No material on this site/app is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website/app.
Copyright © 2025,Curbside and related marks are registered trademarks of Curbside Tech Inc.
